Third-line treatment with second-generation tyrosine kinase inhibitors (dasatinib or nilotinib) in patients with chronic myeloid leukemia after two prior TKIs: real-life data on a single center experience along with the review of the literature

Creative Commons License

Ongoren S., Eskazan A., Suzan V., Savci S., Erdogan O., Berk S., ...Daha Fazla

Hematology, cilt.23, sa.4, ss.212-220, 2018 (SCI-Expanded, Scopus) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 23 Sayı: 4
  • Basım Tarihi: 2018
  • Doi Numarası: 10.1080/10245332.2017.1385193
  • Dergi Adı: Hematology
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.212-220
  • Anahtar Kelimeler: Chronic myeloid leukemia, dasatinib, imatinib, nilotinib, third-line treatment, tyrosine kinase inhibitor, CHROMOSOME-POSITIVE LEUKEMIAS, CHRONIC MYELOGENOUS LEUKEMIA, PATIENTS RECEIVING IMATINIB, CHRONIC-PHASE, EUROPEAN LEUKEMIANET, FOLLOW-UP, THERAPY, FAILURE, RESISTANCE, RECOMMENDATIONS
  • Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
  • İstanbul Üniversitesi-Cerrahpaşa Adresli: Evet

Özet

© 2017 Informa UK Limited, trading as Taylor & Francis Group.Objectives: Newer tyrosine kinase inhibitors (TKIs) (bosutinib, ponatinib) and allogeneic hematopoietic stem cell transplantation (allo-HSCT) can be utilized as a salvage therapy in patients with chronic myeloid leukemia (CML) who failed two lines (imatinib → nilotinib or imatinib → dasatinib) of TKI therapy. However, these TKIs are not available in many countries and not all patients can undergo allo-HSCT. Methods: In this study, CML patients who received dasatinib or nilotinib as a third-line treatment were retrospectively evaluated. Results: Out of 209 patients, third-line dasatinib/nilotinib was administered in 21. During the follow-up, 16 out of 21 patients gained and/or maintained an optimal response, and 4 patients died due to progression. Seventeen patients were alive at the time of the analysis, of which 13 were still on TKI, whereas 4 patients quit treatment. Discussion: In patients failing two lines of TKI, dasatinib or nilotinib can be beneficial and safely administered as a third-line treatment especially in nations with restricted resources.